Trials / Unknown
UnknownNCT05128331
sPERMIdine supplemenTation on Metabolic, Neuronal and Cardiovascular Response to Exercise TRAINING
The Effect of sPERMIdine supplemenTation on the Metabolic, Neuronal and Cardiovascular Response to Exercise TRAINING in Patients With Heart Failure With Preserved Ejection Fraction
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- University Medicine Greifswald · Academic / Other
- Sex
- All
- Age
- 50 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study explores whether spermidine supplementation improves the metabolic, neurological-cognitive and cardiovascular response to structured exercise training in patients with heart failure with preserved ejection fraction. The investigators aim to show that a faster adaptation to exercise may improve long term adherence to a more active lifestyle.
Detailed description
Heart failure with preserved ejection fraction is the largest unmet need in medicine. Exercise training is a pivotal lifestyle intervention which has been shown to have beneficial effects with regards to metabolic, neurological-cognitive and cardiovascular outcomes in these patients. Yet, not every patients responds equally fast to an exercise training intervention. This trial explores whether the supplementation of spermidine can increase the response to a structured aerobic exercise training. The investigators will recruit 30 patients who will either receive a spermidine supplement or a placebo. The study participants are invited for a first follow-up visit after four weeks. The exercise intervention starts at week 5 and continues for 12 weeks. Hence, overall there are three visits (baseline, week four and week twelve).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | spermidineLife | dietary supplement that is made of natural wheat germ extract with high spermidine content |
| DIETARY_SUPPLEMENT | Placebo | dietary supplement that is made of cellulose. |
Timeline
- Start date
- 2021-08-11
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2021-11-22
- Last updated
- 2022-05-25
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05128331. Inclusion in this directory is not an endorsement.